Hospital San Pedro De Alcantara
- Address
- lock Available on a paid plan
Hematology and Blood Cancers
At Hospital San Pedro De Alcantara in Caceres, much of the clinical research focuses on hematologic malignancies and related blood disorders. Studies are aimed at improving treatment effectiveness, testing new combinations, and finding better options for people with difficult-to-treat disease.
- Acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia
- Multiple myeloma and plasma cell disorders
- Lymphomas such as diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia
The site’s work in hematology is especially active in evaluating new therapies for relapsed or high-risk disease, with the goal of improving response rates and long-term outcomes.
Breast Cancer and Other Solid Tumors
Another major research area at this Spanish hospital is oncology, particularly breast cancer and other solid tumors. These trials are designed to refine treatment choices, support earlier intervention, and help match therapy to tumor biology.
- HER2-positive, HR-positive, and HER2-negative breast cancer
- Triple-negative breast cancer and advanced metastatic breast cancer
- Melanoma, ovarian cancer, pancreatic cancer, and lung cancer
Research here often evaluates new targeted and immune-based approaches, as well as strategies to improve outcomes after surgery or in advanced disease.
Genitourinary and Kidney Cancer Research
Clinical trials also cover genitourinary cancers, with a strong focus on bladder cancer, prostate cancer, and kidney cancer. The purpose is to improve disease control, reduce recurrence, and broaden treatment options for patients with localized or advanced disease.
- Muscle-invasive and non-muscle invasive bladder cancer
- Metastatic prostate cancer
- Renal cell carcinoma and recurrence prevention after surgery
These studies reflect a growing interest in both immunotherapy and perioperative treatment approaches to improve outcomes in urologic cancers.
Immune, Inflammatory, and Rare Blood Conditions
The site’s portfolio includes research in immune system diseases and rare inflammatory conditions, alongside selected non-malignant blood disorders. These trials aim to better control inflammation, prevent disease flares, and compare newer therapies with established care.
- Paroxysmal nocturnal hemoglobinuria and immune thrombocytopenia
- Myelofibrosis and neutropenia linked to intensive cancer treatment
- Autoinflammatory diseases and other rare immune-mediated disorders
Work in this area combines diagnostic and therapeutic research to support more precise and better-tolerated care.
Cardiovascular, Respiratory, and Neurologic Studies
Beyond cancer and hematology, Hospital San Pedro De Alcantara participates in trials across cardiovascular disease, respiratory disease, and selected neurologic conditions. These studies focus on improving prevention, symptom control, and long-term disease management.
- Acute coronary syndromes, atherosclerotic cardiovascular disease, and aortic valve stenosis
- Chronic obstructive pulmonary disease and asthma
- Intracerebral hemorrhage and other serious neurologic events
Research in these fields often compares current standard care with newer strategies to improve safety, reduce complications, and support better everyday function.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 236 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 227 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 55 by active trials.
- 1Novartis Pharma AG2active
lock +54 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG7trials
lock +27 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital San Pedro De Alcantara
lock Showing 1 of 140 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 236 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 9 | Unknown | 2018-04-12 | 2026-05-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.